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Abstract
Introduction: Recent, international declines in breast cancer incidence are unprecedented, and the causes remain
controversial. Few data sources can address breast cancer incidence trends according to pertinent characteristics
like hormone therapy use history.
Methods: We used the prospective California Teachers Study to evaluate changes in self-reported use of
menopausal hormone therapy (HT) between 1995 to 1996 and 2005 to 2006 and age-adjusted breast cancer
incidence among 74,647 participants aged 50 years or older. Breast cancer occurrence was determined by linkage
with the California Cancer Registry.
Results: During 517,286 woman years of follow up, 565 in situ and 2,668 invasive breast cancers were diagnosed.
In situ breast cancer incidence rates in this population did not change significantly from 2000 to 2002 to 2003 to
2005, whereas rates of invasive breast cancer declined significantly by 26.0% from 528.0 (95% confidence intervals
(CI) = 491.1, 564.9) per 100,000 women in 2000 to 2002 to 390.6 (95% CI = 355.6, 425.7) in 2003 to 2005. The
decline in invasive breast cancer incidence rates was restricted to estrogen receptor-positive tumors. In 1996 to
1999 and 2000 to 2002 invasive breast cancer incidence was higher for women who reported current HT use
especially estrogen-progestin (EP) use at baseline than for never or past users; but by 2003 to 2005 rates were
comparable between these groups. For women who were taking EP in 2001 to 2002,75% of whom had stopped
use by 2005 to 2006, incidence had declined 30.6% by 2003 to 2005 (P = 0.001); whereas incidence did not
change significantly for those who never took HT (P = 0.33).
Conclusions: Few data resources can examine prospectively individual HT use and breast cancer diagnosis. Stable
in situ breast cancer rates imply consistent levels of screening and suggest recent declines in invasive breast cancer
to be explained predominantly by changes in HT use.
Introduction
Several reports document recent declines in the inci-
dence of invasive breast cancer in the US [1-7] and
throughout developed countries [8-13]. The reasons for
and timing of these declines is controversial. Most
researchers have suggested that the sharp decline
observed in 2002 followed widespread reductions in pre-
scribing [14] and use of menopausal hormone therapy
(HT) [15], after the July 2002 media coverage of the
early termination of the Women’s Health Initiative trial
of estrogen-progestin (EP) therapy [16]. However, others
have argued that changes in mammography use are
more likely to be responsible, because subtle declines in
breast cancer incidence began in 1999, predating publi-
cation of the Women’s Health Initiative trial results, and
because of the uncertain biological plausibility of an
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sharp decrease in breast cancer incidence in 2002 was
reported by at least one cohort defined by regular mam-
mography use [4], but thus far, data documenting inci-
dence trends among women according to their personal
HT use are very limited. The ongoing California Tea-
chers Study (CTS) cohort has collected information on
participants’ HT use periodically since 1995-1996 and is
a population with high rates of mammographic screen-
ing and HT use [17]. Capitalizing on the capacity to
examine long-term trends according to personal HT use
history in the CTS, we evaluated changes in breast can-
cer occurrence over the period from 1996-2005.
Materials and methods
The CTS, a cohort of female public school teachers and
administrators, was established in 1995-1996 to study
breast cancer and other women’s health issues [17]. The
study protocol was approved by the institutional review
boards of participating institutions. Participants reported
their menopausal status and HT use on the baseline
questionnaire. Information on HT use was updated in
2000-2001. This analysis of incidence rates of breast
cancer was limited to women who were California resi-
dents at baseline and who had no history of in situ or
invasive breast cancer (n = 118,261). Women who were
premenopausal (n = 12,908), had missing data on HT
use at baseline or in the 2000-2001 follow-up question-
naire (n = 3222), or did not achieve the age of 50 years
(n = 27,484) during the course of the follow-up period
(1995-2005) were ineligible for the analyses. As hor-
mones may be taken during the menopausal transition
[15], we included women who were either perimenopau-
sal (defined as women who reported that their men-
strual periods had stopped within the past six months),
postmenopausal (defined as women who reported that
their menstrual periods had stopped more than six
months ago), or those whose menopausal status was
unknown because they were taking HT. As women who
were aged 40-49 years at baseline turned 50 years dur-
ing the follow-up period, they were entered into the
analyses. A total of 74,647 women were included in the
analyses. HT use was categorized as ‘never’, ‘past’,o r
‘current’ in 1995-1996 according to the baseline ques-
tionnaire and during follow up in 2000-2001 according
to the third questionnaire. For descriptive purposes
only, we evaluated how many women had stopped or
started HT by the end of follow up in 2005, by examin-
ing HT use among 44,108 women who additionally
answered HT questions on the 2005-2006 questionnaire.
This information is used to illustrate changes in HT use
that occurred after 2000-2001; however, the small num-
ber of breast cancers that occurred in the interval
between 2000-2001 and 2005-2006 precluded subgroup
analyses. Informed consent of participants was implied
by questionnaire completion.
Incident diagnoses of invasive and in situ breast can-
cer (International Classification of Diseases for Oncol-
ogy, Third Edition (ICD-O-3) site codes 500-509,
excluding morphology codes 9590-9989) were identified
by annual linkage with the California Cancer Registry
[18]. Cancer data were complete through to 31 Decem-
ber, 2005. The cohort was followed from the date of
completion of the baseline questionnaire until the ear-
liest of the following events: the date of first in situ or
invasive breast cancer diagnosis, date of death, date of
move outside of California, or 31 December, 2005. Con-
tinued California residence was self reported on three
follow-up questionnaires and was supplemented by the
information obtained from the US Postal Service
National Change of Address database and change of
address cards provided in the annual newsletter that
were submitted by participants. Deaths were identified
through annual probabilistic record linkage to the Cali-
fornia state mortality file, the national Social Security
Administration death master file and the National
Death Index. Women who moved out of state or died
during a calendar year contributed woman months of
follow up until the month of move or death. Woman
years, as the denominators for incidence rates for each
period of analysis, were accrued based on the above
described eligibility criteria and are shown in Table 1.
We used SAS version 9.2 (SAS Institute, Cary, NC,
USA) to calculate age-adjusted incidence rates per
100,000 woman years, standardized to the 2000 US
population (10 age groups - Census P25-1130), and cor-
responding 95% confidence intervals (CI) for three dis-
tinct time periods; 1996-1999, 2000-2002, and 2003-
2005, a) for invasive breast cancer overall, and by estro-
gen receptor (ER) status and for in situ breast cancer,
b) according to HT use reported at baseline, and c)
according to HT use reported in 2000-2001. We did
not have adequate numbers of cases to conduct regres-
sion-based assessments of trends, thus we calculated
95% CI and tested whether the changes between time
period-specific rates were statistically significant, treat-
ing 2000-2002 as the reference group, using a z score
[19]. Where multiple time periods were assessed the P
values were adjusted for multiple comparisons using a
Bonferroni correction [20].
All analyses were repeated to determine the influence
of including a small number of women who reported on
the baseline questionnaire that they did not receive reg-
ular screening for breast cancer. Observed trends were
essentially unchanged whether including or excluding
these unscreened women. Therefore, we present below
results including all women regardless of the regularity
of their mammographic screening.
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During 517,286 woman years of follow up, 566 in situ
and 2668 invasive breast cancers were diagnosed.
Among the invasive tumors, 1945 (72.9%) were ER posi-
tive; 324 (12.1%) were ER negative; and 399 (15.0%)
were borderline or ER status was unknown (Table 1). At
baseline, 26.5% of age-eligible participants had never
taken HT, 59.9% were current users and 13.5% were
past users. In 2000-2001, with an additional 5599
women having aged into the analysis cohort, 23.0% were
classified as never HT users, 57.7% were current users
and 19.3% were past users. By 2005-2006, 26.9% had
never taken HT, 21.0% reported current use and 52.1%
were past users. By the end of follow up in 2005-2006,
75.0% of those reporting current EP use in 2000-2001,
and 55.8% of those reporting current estrogen-only HT
use, had stopped HT use.
Baseline characteristics according to HT use history
Compared with women who had never taken HT, cur-
rent users were more likely to be younger and non-His-
panic white (Table 1). Current EP users were more
likely than estrogen-only HT users, or past or never HT
users to live in an area with the highest socioeconomic
status and were much less likely to be overweight or
obese. Women who had never taken HT were less likely
to have had their first full-term pregnancy before age 35
years. Family history of breast cancer, age at menarche
and alcohol intake did not differ by HT use history.
Breast cancer incidence rates
Overall, age-adjusted incidence rates of in situ breast
cancer did not change substantially (change from 1996-
1999 to 2000-2002, P = 0.09; from 2000-2002 to 2003-
2005, P = 0.24; Figure 1). However, incidence rates of
invasive breast cancer peaked in 2000-2002, and then
declined by 26.0% from 528.0 (95% CI = 491.1 to 564.9)
per 100,000 women in 2000-2002 to 390.6 (95% CI =
355.6 to 425.7) per 100,000 woman years in 2003-2005
(Table 2). The decline in rates from 2000-2002 to 2003-
2005 was statistically significant (P < 0.001). Examining
trends separately by ER status, declines were limited to
ER-positive cancer, for which rates peaked in 2000-2002
at 390.6 per 100,000 woman years before declining
24.8% to 293.8 in 2003-2005 (P < 0.001). Rates of ER-
negative cancer were generally stable throughout the
time period; the slight 14.1% decline in rates between
2000-2002 and 2003-2005 was not statistically signifi-
cant (P = 0.38). Among women with invasive breast
cancer, 77.8% with ER-positive disease and 70.4% with
ER-negative disease reported having used HT at some
time on their baseline questionnaire.
Incidence rates by HT use history
Figure 2 shows invasive and in situ breast cancer inci-
dence trends according to HT use reported on the base-
line questionnaire. Women who reported currently
taking EP at baseline had consistently higher rates of
invasive and in situ breast cancer than estrogen-only
HT users or never or past HT users. Whereas the age-
adjusted incidence rates of invasive breast cancer
between 2000-2002 and 2003-2005 were stable for never
users and past users of HT, among women who
reported current use of EP at baseline, incidence rates
declined significantly by 45.8% from 782.7 (95% CI =
687.1 to 878.2) per 100,000 in 2000-2002 to 424.6 (95%
CI = 353.5 to 495.7) in 2003-2005 (P < 0.001; Table 3).
Women currently taking EP also experienced the largest
decline in rates of in situ cancer (percent change =
-46.7, P = 0.008). Declines in breast cancer rates among
current E users were also observed (invasive percent
change = -26.1%, P = 0.010; in situ percent change =
-23.3%, P = 0.23).
HT use was reassessed on a second questionnaire
administered in 2000. Breast cancer incidence was cal-
culated for two time periods 2001-2002 and 2003-2005
Table 1 Age-standardized baseline characteristics of menopausal women in the California Teachers Study according to
hormone therapy (HT) use in 1995-1996
Never HT
(n = 14,070)
Past HT
(n = 7914)
Current E
(n = 15,407)
Current EP
(n = 16,934)
Mean age in years 66.5 68.2 63.3 58.9
% Non-Hispanic white 85.3 87.9 90.1 92.2
% First-degree family history of breast cancer 15.2 14.9 13.2 12.2
% BMI overweight or obese ≥25 kg/m
2 45.2 45.2 41.6 34.9
% High alcohol intake (average ≥20 g/day) 8.6 9.3 9.5 10.4
% Highest quartile of residential socioeconomic status 44.4 44.8 47.5 52.5
% Menarche at age 11 years or younger 22.0 23.4 23.6 20.9
% Nulliparous 23.5 19.5 18.8 19.5
% Parous before age 35 years 70.2 74.8 76.3 75.1
BMI = body mass index; E = estrogen only; EP = estrogen and progestin combined therapy.
Age-standardized by 10-year age categories to the age distribution of menopausal women in analysis.
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2000-2001. Figure 3 and Table 4 show that during this
time, invasive and in situ breast cancer rates declined
for all categories of HT users, except for women who
had never taken HT, in whom there was a non-signifi-
cant increase of 23.8% in in situ breast cancer between
the two time periods. Age-adjusted incidence rates for
invasive breast cancer declined rapidly for women who
had stopped HT by 2000-2001 (’past HT use’)f r o m
561.1 (95% CI = 432.4 to 689.8) per 100,000 women in
2001-2002 to 340.0 (95% CI = 265.6 to 414.4) per
100,000 in 2003-2005, an overall decline of 39.4% (P =
0.003). A similar decline was observed for women who
were current users of EP in 2000-2001 (percent change =
-30.6, P = 0.001), and to a lesser extent, for current estro-
gen-only HT users (percent change = -24.0, P =0 . 0 3 0 ) .
0
100
200
300
400
500
600
700
1996-99 2000-02 2003-05
A
g
e
-
a
d
j
u
s
t
e
d
 
i
n
c
i
d
e
n
c
e
 
r
a
t
e
 
p
e
r
 
1
0
0
,
0
0
0
 
w
o
m
e
n
Invasive
ER positive
In situ
ER negative
Figure 1 Age-adjusted incidence rates of breast cancer according to type of tumor and estrogen receptor (ER) status of invasive
cancers among menopausal women 50 years or older in the California Teachers Study.
Marshall et al. Breast Cancer Research 2010, 12:R4
http://breast-cancer-research.com/content/12/1/R4
Page 4 of 9Table 2 Age-adjusted incidence rate (AAIR) of breast cancer, according to type of tumor and estrogen receptor (ER)
status of invasive cancers among menopausal women in the California Teachers Study
Period Woman In situ Invasive ER positive ER negative
years n AAIR (95% CI) n AAIR (95% CI) n AAIR (95% CI) n AAIR (95% CI)
1996-99 208,860 207 95.2 (81.6-108.7) 1072 501.7 (470.3-533.1) 765 358.7 (332.1-385.3) 127 59.5 (48.6-70.3)
2000-02 158,917 197 113.7 (96.5-130.9) 914 528.0 (491.1-564.9) 676 390.6 (358.8-422.3) 103 59.4 (46.9-71.9)
2003-05 149,509 161 98.2 (79.1-117.3) 682 390.6 (355.6-425.7) 504 293.8 (261.9-325.7) 94 51.0 (40.5-61.5)
Total cases 565 2668 1945 324
% change
1996-99 to 2000-02
19.4% P = 0.09 5.2% P = 0.30 8.9% P = 0.13 -0.2% P = 0.99
% change
2000-02 to 2003-05
-13.6% P = 0.24 -26.0% P < 0.001 -24.8% P < 0.001 -14.1% P = 0.38
CI = confidence interval.
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Figure 2 Age-adjusted incidence rates of invasive (solid lines) and in situ (dashed lines) breast cancer according to hormone therapy
use at baseline in 1995-1996 among menopausal women 50 years or older in the California Teachers Study. E = estrogen only
hormone therapy; EP = estrogen-progestin hormone therapy; HT = Hormone therapy.
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Page 5 of 9Table 3 Age-adjusted incidence rate (AAIR) of invasive and in situ breast cancer according to hormone therapy (HT)
use at baseline in 1995-1996 among menopausal women in the California Teachers Study
Period Never HT Past HT Current E Current EP
AAIR (95% CI) AAIR (95% CI) AAIR (95% CI) AAIR (95% CI)
Invasive breast cancer
1996-99 399.0 (341.7-456.3) 343.7 (268.8-418.6) 567.5 (501.1-633.9) 680.8 (576.7-784.8)
2000-02 334.7 (278.5-390.9) 410.6 (300.7-520.6) 509.6 (438.9-580.2) 782.7 (687.1-878.2)
2003-05 374.1 (308.1-440.1) 297.8 (218.5-377.2) 376.4 (314.7-438.1) 424.6 (353.5-495.7)
% change
1996-99 to 2000-02
-16.1% P = 0.13 19.5% P = 0.31 -10.2% P = 0.11 15.0% P = 0.016
% change
2000-02 to 2003-05
11.8% P = 0.38 -27.5% P = 0.17 -26.1% P = 0.010 -45.8% P < 0.001
In Situ breast cancer
1996-99 65.0 (41.1-88.9) 87.5 (43.2-131.7) 85.4 (60.2-110.6) 187.0 (128.3-245.6)
2000-02 64.5 (39.5-89.6) 96.6 (29.7-163.5) 107.5 (78.1-136.9) 169.2 (128.6-209.9)
2003-05 103.1 (60.5-145.7) 131.7 (163.5-160.6) 82.4 (56.5-108.3) 90.1 (65.4-114.8)
% change
1996-99 to 2000-02
-0.8% P = 0.98 10.4% P = 0.82 25.9% P = 0.12 -9.5% P = 0.38
% change
2000-02 to 2003-05
59.8% P = 0.10 36.3% P = 0.51 -23.3% P = 0.23 -46.7% P = 0.008
CI = confidence interval; E = estrogen only; EP = estrogen and progestin combined therapy.
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Figure 3 Age-adjusted incidence rates of invasive (solid lines) and in situ (dashed lines) breast cancer according to hormone therapy
use at follow-up in 2000-2001 among menopausal women 50 years or older in the California Teachers Study. E = estrogen only
hormone therapy; EP = estrogen-progestin hormone therapy; HT = Hormone therapy.
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Page 6 of 9For never users of HT, invasive incidence trends were
stable between the two time periods 2001-2002 (percent
change = -6.9, P = 0.33). None of the changes in rates
observed for in situ breast cancer were statistically
significant.
Discussion
Researchers using ecologic study designs have only been
able to speculate that HT is responsible for the unprece-
dented decline in invasive breast cancer incidence
observed in 2002 [1,2,14,21]. With the individual-level
i n f o r m a t i o no nH Tu s eh i s t o r yi no u rp r o s p e c t i v e
cohort, we are able to show several important phenom-
ena regarding breast cancer occurrence in this popula-
tion: 1) 24.8% decline in ER-positive breast cancer
occurring between 2000-2002 and 2003-2005 while ER-
negative breast cancer remained stable; 2) incidence
trends that varied substantially by HT use at baseline,
with consistently higher rates among current HT users
particularly EP users, than never users; 3) 45.8% decline
in breast cancer incidence from 2000-2002 to 2003-2005
observed among women who were current EP users in
2000-2002, the majority of whom (75.0%) were likely to
have ceased use by 2005, but not among women who
had never used HT; and 4) stable rates among women
who reported never having any HT use. Thus, these
data provide further support for the stronger etiologic
importance of current versus past HT use in breast can-
cer risk.
Among women reporting that they stopped using HT,
rates of invasive breast cancer rapidly declined. This is
demonstrated by both the trends in incidence among
women who had stopped use by 2000-2001 (’past users’)
who had a 39.4% drop in rates and the trends in inci-
dence among women who were still taking EP in 2000-
2001, but who had largely stopped use by 2005-2006.
Taken together, our observations demonstrate a strong
and immediate influence of HT use and cessation on
breast cancer occurrence [21].
The CTS population reports near uniformity with
respect to screening compliance. Nearly 97% of CTS
participants aged over 50 years at baseline reported
being current with mammography guidelines at baseline.
Stable in situ breast cancer rates and stable invasive
breast cancer rates among women who had never taken
HT imply consistent levels of screening throughout the
study period and screening rates are particularly high
for this population [17]. Furthermore, when we
restricted our analyses to those 97% that were current
with breast health screening at the start of our study,
the results did not change, and similar declines in breast
cancer incidence have been reported from populations
of women screened uniformly [4]. Other researchers
have even suggested increased usage of mammography
[22]. Clearly, any possible influence of ‘mammography
saturation’ or other screening effects will be smaller and
more gradual than the recent rapid declines that we
suggest are attributable to the dramatic changes in HT
use.
We observed large declines in breast cancer incidence;
up to 45.8% among current EP users. We feel that this
decline can be attributed mostly or entirely to HT use
for several reasons: a) this cohort reported high levels of
HT use at baseline - more than 70% of menopausal
women reported ever taking HT; b) this cohort experi-
enced a large decline in HT use - 75% of the EP users
had stopped taken it by 2005 and 56% of the estrogen-
only HT alone users had also stopped; c) some studies
report more than 66% increased risk due to HT use
[23]; and d) the largest declines we observed were in
groups that are plausible biologically - that is, current or
recent EP users, and in ER-positive tumors. In fact the
size and speed of the declines we observed make it unli-
kely that changes in other risk factors including repro-
ductive history, body mass index, diet or alcohol use are
attributable. Some authors [24] have postulated that the
increased use of other medications such as raloxifene
and tamoxifen may be partly responsible for reducing
Table 4 Age-adjusted incidence rate (AAIR) of invasive and in situ breast cancer according to hormone therapy (HT)
use at follow-up in 2000-2001 among menopausal women in the California Teachers Study
Period Never HT Past HT Current E Current EP
AAIR (95% CI) AAIR (95% CI) AAIR (95% CI) AAIR (95% CI)
Invasive breast cancer
2001-02 369.3 (285.6-452.9) 561.1 (432.4-689.8) 534.9 (424.7-645.1) 665.8 (565.9-765.7)
2003-05 343.7 (272.8-414.5) 340.0 (265.6-414.4) 406.4 (324.7-488.0) 461.9 (392.5-531.4)
% change -6.9% P = 0.33 -39.4% P = 0.003 -24.0% P = 0.030 -30.6% P = 0.001
In Situ breast cancer
2001-02 86.6 (44.0-129.1) 100.5 (32.4-168.6) 137.7 (83.2-192.3) 135.0 (95.2-174.9)
2003-05 107.2 (63.1-151.3) 99.5 (60.3-138.8) 123.6 (67.3-179.9) 115.5 (78.1-152.8)
% change 23.8% P = 0.26 -1.0% P = 0.49 -10.2% P = 0.35 -14.4% P = 0.22
CI = confidence interval; E = estrogen only; EP = estrogen and progestin combined therapy.
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CTS in 2005-2006 was very low (about 8.2%) compared
with HT.
A l t h o u g ho u rd a t ac o m ef r o mo n eo ft h el a r g e s tp r o -
spective cohorts tracking HT use, we still had limited
statistical power to detect changes in annual breast can-
cer incidence, especially for disease subgroups. Like
prior population-based studies, we also found that
decreases in breast cancer incidence were only observed
for ER-positive cancers [2-4];h o w e v e r ,w ed i dn o th a v e
a sufficient number of cases to examine trends of ER-
defined breast cancers according to HT use, nor could
we examine duration of HT use.
Conclusions
Along with other studies reaching similar conclusions
[1,2,25], our data provide further evidence that recent
declines in invasive breast cancer incidence in the US
are explained predominantly by decreased HT use.
Abbreviations
CI: confidence intervals; CTS: California Teachers Study; ER: estrogen receptor;
EP: estrogen-progestin hormone therapy; HT: Hormone therapy.
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